Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor-based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus-infected patients. Thus, we performed a 24-week real-life observational study to assess efficacy and safety of switching from raltegravir plus etravirine to dolutegravir plus rilpivirine in 7 previously heavily treated patients. This simplification strategy reduced pill burden and preserved viral suppression in treatment-experienced patients with no major mutations to rilpivirine at historical genotyping.

Maintenance of viral suppression after optimization therapy from etravirine plus raltegravir to rilpivirine plus dolutegravir in HIV-1-infected patients / N. Riccardi, F. Del Puente, L. Taramasso, A. Di Biagio. - In: JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. - ISSN 2325-9582. - 18:(2019 Jan), pp. 2325958218821657.1-2325958218821657.3. [10.1177/2325958218821657]

Maintenance of viral suppression after optimization therapy from etravirine plus raltegravir to rilpivirine plus dolutegravir in HIV-1-infected patients

N. Riccardi
;
L. Taramasso;
2019

Abstract

Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor-based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus-infected patients. Thus, we performed a 24-week real-life observational study to assess efficacy and safety of switching from raltegravir plus etravirine to dolutegravir plus rilpivirine in 7 previously heavily treated patients. This simplification strategy reduced pill burden and preserved viral suppression in treatment-experienced patients with no major mutations to rilpivirine at historical genotyping.
dolutegravir; dual-therapy; optimization; rilpivirine
Settore MED/17 - Malattie Infettive
gen-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
Riccardi JIAPAC.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 64.7 kB
Formato Adobe PDF
64.7 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/708202
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact